/FROM PR NEWSWIRE DALLAS 888-776-3971/
STK NASDAQ-NMS:MAKO
IN HEA MTC MEQ SPM
SU TDS
TO BUSINESS, HEALTH, AND MEDICAL EDITORS:
MAKO Surgical Corp. Showcases MAKOplasty@ Total Hip Arthroplasty at
American Academy of Orthopaedic Surgeons 2012 Annual Meeting
SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- MAKO Surgical Corp.
(NASDAQ: MAKO), a leader in robotic arm assisted partial knee
arthroplasty worldwide, today announced the MAKOplasty@ Total Hip
Arthroplasty (THA) application will be featured at the American
Academy of Orthopaedic Surgeons 2012 Annual Meeting (AAOS) being held
on February 7-11, 2012 at the Moscone Center in San Francisco,
California.
MAKOplasty@ THA is the newest application for MAKO's RIO@ Robotic Arm
Interactive Orthopedic System. The RIO@ system will be on exhibit at
MAKO's AAOS Annual Meeting Booth ‥2353. During the meeting,
experienced MAKOplasty@ orthopedic surgeons will give presentations
and hands-on demonstrations of the MAKOplasty@ THA application.
"There is clearly a need for precision and accuracy in total hip
replacement. We believe the RIO@ system, which enables surgeons to
achieve consistently reproducible precision for the individual
patient, along with our MAKOplasty@ THA, are key drivers in leading
our growing presence in orthopedic surgery," said Maurice R. Ferre,
M.D., president and CEO of MAKO.
MAKOplasty@ THA builds upon MAKOplasty@ Partial Knee Resurfacing's
proven benefits for patients with early to mid-stage osteoarthritis of
the knee. To date, nearly 13,000 patients have benefited from
MAKOplasty@ partial knee and total hip procedures. In 2012, MAKO
anticipates to perform 11,000 to 13,000 MAKOplasty@ procedures.
MAKOplasty@ THA was introduced in 2011 and is designed to support a
surgeon's ability to more accurately align and position a hip implant
relative to the specific needs of a patient. It provides a surgeon
with a pre-operative 3-D reconstruction of a patient's hip that is
used to develop a patient-specific surgical plan. The surgeon then
uses the RIO@ robotic arm during the procedure to prepare the joint
and optimally place the hip implant to the plan.
As of December 31, 2011, 49 MAKOplasty@ THA applications have been
sold in the U.S.; hospitals in California, New York, and Florida are
among many locations nationwide now offering MAKOplasty@ THA.
More information about MAKOplasty@ can be found at
http://makoplasty.com.
About MAKO Surgical Corp. MAKO Surgical Corp. is a medical device
company that markets its RIO@ Robotic-Arm Interactive Orthopedic
system, joint specific applications for the knee and hip, and
proprietary RESTORIS@ implants for orthopedic procedures called
MAKOplasty@. The RIO is a surgeon-interactive tactile surgical
platform that incorporates a robotic arm and patient-specific
visualization technology, which enables precise, consistently
reproducible bone resection for the accurate insertion and alignment
of MAKO's RESTORIS implants. The MAKOplasty solution incorporates
technologies enabled by an intellectual property portfolio including
more than 300 U.S. and foreign, owned and licensed, patents and patent
applications. Additional information can be found at
www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding,
among other things, statements related to expectations, goals, plans,
objectives and future events. MAKO intends such forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Reform Act of 1995. In
some cases, forward-looking statements can be identified by the
following words: "may," "will," "could," "would," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict,"
"project," "potential," "continue," "ongoing," "guidance" or the
negative of these terms or other comparable terminology, although not
all forward-looking statements contain these words. Examples of such
statements include, but are not limited to, statements about the
nature, timing and number of planned new product introductions; market
acceptance of MAKOplasty, including the RIO system, and MAKO RESTORIS@
family of implant systems; the future availability from third-party
suppliers, including single source suppliers, of implants for and
components of the RIO system; the anticipated adequacy of our capital
resources to meet the needs of MAKO's business; MAKO's ability to
sustain, and MAKO's goals for, sales and earnings growth including
projections regarding systems installations; and MAKO's success in
achieving timely approval or clearance of products with domestic and
foreign regulatory entities. These statements are based on the current
estimates and assumptions of our management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by forward-looking
statements, many of which are beyond MAKO's ability to control or
predict. Such factors, among others, may have a material adverse
effect on MAKO's business, financial condition and results of
operations and may include the potentially significant impact of a
continued economic downturn or delayed economic recovery on the
ability of MAKO's customers to secure adequate funding, including
access to credit, for the purchase of MAKO's products or cause MAKO's
customers to delay a purchasing decision, changes in competitive
conditions and prices in MAKO's markets, unanticipated issues relating
to intended product launches, decreases in sales of MAKO's principal
product lines, decreases in utilization of MAKO's principal product
line or in procedure volume, increases in expenditures related to
increased or changing governmental regulation or taxation of MAKO's
business, both nationally and internationally, unanticipated issues in
complying with domestic or foreign regulatory requirements related to
MAKO's current products or securing regulatory clearance or approvals
for new products or upgrades or changes to MAKO's current products,
the impact of the recently enacted United States healthcare reform
legislation on hospital spending, reimbursement, and the taxing of
medical device companies, the potential impact of the informal
Securities and Exchange Commission inquiry and the findings of that
inquiry, loss of key management and other personnel or inability to
attract such management and other personnel and unanticipated
intellectual property expenditures required to develop, market, and
defend MAKO's products. These and other risks are described in greater
detail under Item 1A, "Risk Factors," in MAKO's periodic filings with
the Securities and Exchange Commission, including MAKO's annual report
on Form 10-K for the year ended December 31, 2010 filed on March 10,
2011 and quarterly report on Form 10-Q for the quarter ended September
30, 2011 filed on November 9, 2011. Given these uncertainties, undue
reliance should not be placed on these forward-looking statements.
MAKO does not undertake any obligation to release any revisions to
these forward-looking statements publicly to reflect events or
circumstances after the date of this press release or to reflect the
occurrence of unanticipated events.
"MAKOplasty@," "RESTORIS@," "RIO@," as well as the "MAKO" logo,
whether standing alone or in connection with the words "MAKO Surgical
Corp." are trademarks of MAKO Surgical Corp.
SOURCE MAKO Surgical Corp.
-0- 02/08/2012
/CONTACT: Media, Yvette Cuello, MAKO Surgical Corp., +1-954-628-0432 (o), +1-954-609-5085 (m), mcuello@makosurgical.com; or Cynthia Kalb, MAKO Surgical Corp., +1-954-628-0426 (o), +1-954-218-9133 (m), ckalb@makosurgical.com; or Lily Eng, Weber Shandwick, +1-415-262-5966, leng@webershandwick.com; or Investors, Susan Verde, MAKO Surgical Corp., +1-954-628-1706, investorrelations@makosurgical.com; or Mark Klausner, Westwicke Partners, +1-443-213-0500, makosurgical@westwicke.com
/Web Site: http://www.makosurgical.com
http://makoplasty.com
(NASDAQ-NMS:MAKO) /
CO: MAKO Surgical Corp.
ST: California
IN: HEA MTC MEQ SPM
SU: TDS
PRN
-- SF49574 --
0000 02/08/2012 13:00:00 EDT http://www.prnewswire.com